BCRX Stock — BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. (BCRX)

Updated October 16, 2026.

BCRX is a Stock. Total return is 19.8% over the past 32.6 years, 2794.7 points behind SPY at 2814.5%.

BioCryst Pharmaceuticals is a biotechnology company developing and commercializing medicines for hereditary angioedema and other rare diseases, with marketed products including RAPIVAB (peramivir injection for influenza) and ORLADEYO (an oral serine protease inhibitor for hereditary angioedema), along with several candidates in clinical development for conditions including netherton syndrome, diabetic macular edema, and atopic dermatitis. The company does not currently have an established distribution program. BioCryst appeals to investors seeking exposure to rare disease therapeutics and clinical-stage drug development rather than current income.

BCRX performance versus SPY

Price and return data through 2026-10-16.

Total return is 19.8% over the past 32.6 years, 2794.7 points behind SPY at 2814.5%. Over the past year its total return — price change plus distributions reinvested — is 15.9%. Its deepest 1-year drawdown was 29.9%.

BCRX key facts

Asset type

Stock

Asset class

Equity

Inception date

03/04/1994

Distribution frequency

None

Last close

$7.79 (as of 2026-10-16)

Market cap

$1,990,618,468

Average volume

4396151.0

Beta

0.548

Payout ratio

0.0%

Forward P/E

14.4928

EPS

$-1.40

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BCRX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 29.9%.

Who may consider BCRX — and who may not

It is a weaker fit for investors who need monthly cash flow (BCRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BCRX

• All tickers starting with B

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions